Background
Phase 3, open-label, 3-arm randomized controlled trial (Alliance A041202). N=547 previously untreated CLL patients aged ≥65 years. Three-arm design: bendamustine-rituximab (BR) vs ibrutinib vs ibrutinib+rituximab. Randomized 1:2:2. Key questions: does adding rituximab to ibrutinib improve outcomes, and does ibrutinib outperform standard CIT in elderly CLL? Median age 71 years. Del(17p) patients permitted.
Interventions and follow up
Arm A: BR: bendamustine 90 mg/m² IV days 1–2 + rituximab 375 mg/m² day 1 cycle 1 then 500 mg/m² day 1 cycles 2–6; 6 cycles q28d (N=183)
Arm B: Ibrutinib 420 mg PO daily continuously (N=182)
Arm C: Ibrutinib 420 mg daily + rituximab 375 mg/m² IV weekly × 4 (cycle 1) then monthly × 5 (N=182); both ibrutinib arms continued until progression or intolerance
Primary endpoint: Progression-free survival (PFS)
Median follow up: 55 months (Woyach Blood 2024 update)
Arm B: Ibrutinib 420 mg PO daily continuously (N=182)
Arm C: Ibrutinib 420 mg daily + rituximab 375 mg/m² IV weekly × 4 (cycle 1) then monthly × 5 (N=182); both ibrutinib arms continued until progression or intolerance
Primary endpoint: Progression-free survival (PFS)
Median follow up: 55 months (Woyach Blood 2024 update)
Results
2-yr PFS: 74% (BR) vs 87% (ibrutinib) vs 88% (ibrutinib+R)
HR (ibrutinib vs BR): 0.39 (95% CI 0.26–0.58), P<.001
HR (ibrutinib+R vs BR): 0.38 (95% CI 0.25–0.59), P<.001
Median PFS (4-yr update): 44 months (BR) vs not reached in either ibrutinib arm; 4-yr PFS 47% (BR) vs 76% (ibrutinib) vs 76% (ibrutinib+R)
OS: No significant difference at any time point
HR (ibrutinib vs BR): 0.39 (95% CI 0.26–0.58), P<.001
HR (ibrutinib+R vs BR): 0.38 (95% CI 0.25–0.59), P<.001
Median PFS (4-yr update): 44 months (BR) vs not reached in either ibrutinib arm; 4-yr PFS 47% (BR) vs 76% (ibrutinib) vs 76% (ibrutinib+R)
OS: No significant difference at any time point
Adverse events
Cardiovascular: Grade ≥3 atrial fibrillation 18% at 4 years (ibrutinib arms); hypertension grade ≥3 14%; adding rituximab did not increase AFib or major bleeding.
Hematologic: Grade ≥3 neutropenia higher with BR (61%) vs ibrutinib (36%).
Infections: Grade ≥3 infections 20% (ibrutinib arms).
Tolerability: Discontinuation due to AEs 26% (ibrutinib), 19% (ibrutinib+R), 15% (BR) at median 55 months.
Hematologic: Grade ≥3 neutropenia higher with BR (61%) vs ibrutinib (36%).
Infections: Grade ≥3 infections 20% (ibrutinib arms).
Tolerability: Discontinuation due to AEs 26% (ibrutinib), 19% (ibrutinib+R), 15% (BR) at median 55 months.
Conclusions
Ibrutinib regimens significantly improved PFS over BR in elderly treatment-naive CLL. Adding rituximab to ibrutinib did not improve PFS, ORR, or OS over ibrutinib alone, establishing ibrutinib monotherapy as the appropriate BTKi backbone. No OS benefit was demonstrated for ibrutinib over BR at 4-year follow-up.
Key Limitations
No OS benefit for ibrutinib despite superior PFS; crossover at progression and effective salvage therapies confound OS. Rituximab addition to ibrutinib provides no benefit, confirming anti-CD20 antibodies add little to continuous BTKi therapy. Long-term ibrutinib associated with cumulative AFib (18%), hypertension, and bleeding. Ibrutinib has now been largely replaced by next-generation BTKi (acalabrutinib, zanubrutinib) with improved cardiac safety. Median age 71 years limits applicability to younger patients.
Clinical Context
Alliance A041202 established ibrutinib as superior to BR in elderly CLL and confirmed ibrutinib monotherapy (not ibrutinib+rituximab) as the appropriate BTKi approach. Ibrutinib is no longer a preferred first-line agent; acalabrutinib (ELEVATE-TN) and zanubrutinib (SEQUOIA, ALPINE) offer comparable efficacy with superior cardiac safety. Fixed-duration venetoclax-based regimens (CLL14, CLL17) provide treatment cessation options. ESMO-MCBS: not assigned.